Systemic Enzymes and Pulmonary Fibrosis

You probably don't think very much about your respiratory system, but it is essential for life. Every once in a while a cough or a sneeze will remind you about this body system. A cough is the way your system clears the airway. A sneeze is caused by an irritation in the upper airway. Most people experience minor respiratory problems in the form of a sore throat, cough, or bronchitis from an illness, but other times more serious lung diseases, which can harm and even destroy the respiratory system, may be present.

Interstitial lung disease describes a group of disorders that cause progressive scarring of lung tissue. This pulmonary fibrosis, or lung scarring, is irreversible. There are more than 100 separate disorders classified as interstitial lung disease, with idiopathic pulmonary fibrosis being the most common. Breathing problems caused by interstitial lung disease may prevent the body from getting enough oxygen into the bloodstream, which can in turn lead to a number of serious complications including a shortened life expectancy.

At this time, treatments for pulmonary fibrosis are extremely limited. In fact, an anti-fibrotic, anti-inflammatory drug that has been approved for use with idiopathic pulmonary fibrosis in other countries has failed to receive approval in the US. While conventional medicine has yet to find a solution to reverse pulmonary fibrosis, systemic enzyme therapy provides hope. Used safely for more than 50 years, systemic enzymes are a natural and effective way to improve the body’s overall response to injury, providing a first line of defense against inflammation.

Serrapeptase and nattokinase are powerful systemic enzymes that act upon protein-based complexes, such as the fibrin that makes up scars, at and around damaged tissue. Nattokinase is particularly effective because it enhances the body's natural ability to fight excess fibrin deposits in several different ways. It dissolves fibrin directly and appears to enhance the body's natural production of both plasmin and other clot-dissolving enzymes. Additionally, research shows serrapeptase significantly reduces the viscosity of mucus in the lungs and nasal passageways, improving airflow.

Systemic enzyme blends which include these powerful proteases can be made a part of an aggressive and continual approach to combatting pulmonary fibrosis. Maintaining a highly therapeutic enzyme program with proper breathing exercises can help control and even reduce many of the problems associated with fibrosis.

Being involved in your own treatment and staying as healthy as possible are essential to living with interstitial lung disease.

 

 

References:

1.   Fujita M, Hong K, Ito Y, et al. Thrombolytic Effect of Nattokinase on a Chemically Induced Thrombosis Model in Rat.  Biol Pharm Bull. 1995; 18(10):1387-1391.

2.   Nakamura S, Hashimoto Y, Mikami M, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. 2003; 8(3):316-20.